Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase – Time to Buy?

Shares of Pharvaris N.V. (NASDAQ:PHVS) saw unusually-high trading volume on Wednesday . Approximately 339,252 shares traded hands during mid-day trading, an increase of 96% from the previous session’s volume of 172,719 shares.The stock last traded at $28.65 and had previously closed at $28.22.

Analyst Ratings Changes

PHVS has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Wolfe Research initiated coverage on shares of Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target for the company. Citigroup reissued a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Royal Bank Of Canada lowered their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Finally, Wedbush raised their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Pharvaris currently has an average rating of “Moderate Buy” and an average price target of $42.73.

Pharvaris Stock Performance

The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -9.20 and a beta of -2.58. The firm’s 50-day simple moving average is $27.62 and its two-hundred day simple moving average is $26.03.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Equities research analysts expect that Pharvaris N.V. will post -3.19 earnings per share for the current fiscal year.

Insider Activity at Pharvaris

In other news, insider Anne Lesage sold 7,000 shares of Pharvaris stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $30.05, for a total transaction of $210,350.00. Following the completion of the sale, the insider owned 156,969 shares in the company, valued at $4,716,918.45. The trade was a 4.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $30.05, for a total transaction of $210,350.00. Following the sale, the director owned 388,167 shares of the company’s stock, valued at approximately $11,664,418.35. This represents a 1.77% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 54,426 shares of company stock worth $1,578,273. 11.84% of the stock is owned by insiders.

Institutional Investors Weigh In On Pharvaris

Institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new stake in shares of Pharvaris during the 4th quarter worth approximately $35,000. JPMorgan Chase & Co. grew its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pharvaris during the 3rd quarter worth approximately $75,000. Barclays PLC acquired a new stake in shares of Pharvaris during the 4th quarter worth approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Pharvaris during the 4th quarter worth approximately $86,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.